Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 19/20 | 0.97 |
| ▸ | GGPS1 | O95749 | 8/20 | 0.97 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.97 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.97 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.64 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.64 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.64 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13308411 | 1.00 | FDPS (0.97) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL5818379 | 0.98 | FDPS (1.00) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL9183 | 0.98 | FDPS (1.00) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL1030766 | 0.97 | FDPS (0.97) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL27857197 | 0.97 | FDPS (0.97) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL1579193 | 0.97 | FDPS (0.97) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL3419518 | 0.97 | FDPS (0.97) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL1240437 | 0.97 | FDPS (0.97) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL3415425 | 0.95 | FDPS (0.93) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL1240197 | 0.95 | FDPS (0.93) | FDPSGGPS1AGTR1OPRM1PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4927814-A | Diphosphonate derivatives, pharmaceutical compositions and methods of use | BOEHRINGER MANNHEIM GMBH (DE) | 1990-05-22 | — | — | US | claimed |
| WO-2011146819-A2 | METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES | DMD THERAPIES, LLC (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
| US-4927814-A | Diphosphonate derivatives, pharmaceutical compositions and methods of use | BOEHRINGER MANNHEIM GMBH (DE) | 1990-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | FDPS 2668/4885GGPS1 2599/4885AGTR1 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.